BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma C, Battat R, Khanna R, Parker CE, Feagan BG, Jairath V. What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity? Best Pract Res Clin Gastroenterol 2019;38-39:101602. [PMID: 31327404 DOI: 10.1016/j.bpg.2019.02.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 D'Arcangelo G, Aloi M. Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say? Paediatr Drugs 2020;22:463-72. [PMID: 32572841 DOI: 10.1007/s40272-020-00406-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kyle BD, Agbor TA, Sharif S, Chauhan U, Marshall J, Halder SLS, Ip S, Khan WI. Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results. J Can Assoc Gastroenterol 2021;4:84-90. [PMID: 33855266 DOI: 10.1093/jcag/gwaa009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Salvador-Martín S, Raposo-Gutiérrez I, Navas-López VM, Gallego-Fernández C, Moreno-Álvarez A, Solar-Boga A, Muñoz-Codoceo R, Magallares L, Martínez-Ojinaga E, Fobelo MJ, Millán-Jiménez A, Rodriguez-Martinez A, Vayo CA, Sánchez C, Tolin M, Bossacoma F, Pujol-Muncunill G, González de Caldas R, Loverdos I, Blanca-García JA, Segarra O, Eizaguirre FJ, García-Romero R, Merino-Bohórquez V, Sanjurjo-Sáez M, López-Fernández LA. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease. Int J Mol Sci 2020;21:E3364. [PMID: 32397546 DOI: 10.3390/ijms21093364] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Zhao H, Liu H, Qi W, Liu W, Ye L, Cao Q, Ge X, Zhou W, Wang X. Postoperative Ratio of C-Reactive Protein to Albumin as a Predictive Marker in Patients with Crohn's Disease Undergoing Bowel Resection. Gastroenterol Res Pract 2021;2021:6629608. [PMID: 33727917 DOI: 10.1155/2021/6629608] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kuai XY, Yu SY, Cui XF, Zhao XJ, Mao XQ, Yu Y, Hu T, Zhang HJ, Zhou CL. LncRNA LUCAT1 as a Plasma Biomarker for Assessing Disease Activity in Adult Patients with Crohn's Disease. Gastroenterol Res Pract 2021;2021:5557357. [PMID: 34621310 DOI: 10.1155/2021/5557357] [Reference Citation Analysis]
6 Danese S, Peyrin-Biroulet L. Evolution of IL-23 Blockade in Inflammatory Bowel Disease. J Crohns Colitis 2022;16:ii1-2. [PMID: 35553668 DOI: 10.1093/ecco-jcc/jjab188] [Reference Citation Analysis]
7 Salvador-Martín S, Bossacoma F, Pujol-Muncunill G, Navas-López VM, Gallego-Fernández C, Viada J, Muñoz-Codoceo R, Magallares L, Martínez-Ojinaga E, Moreno-Álvarez A, Solar-Boga A, Segarra O, Clemente S, Rodriguez-Martinez A, Alvarez-Vayo C, Loverdos I, Merino-Bohórquez V, Balboa-Vega MJ, Blanca-García JA, Fobelo MJ, Millán-Jiménez A, García-Romero R, Sanchez C, Tolín M, Caldas RG, Eizaguirre FJ, Sánchez-Hernandez JG, Torres-Peral R, Aznal E, García-González X, Sanjurjo-Sáez M, López-Fernández LA. Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2020;71:508-15. [PMID: 32773718 DOI: 10.1097/MPG.0000000000002840] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Li L, Chen R, Zhang Y, Zhou G, Chen B, Zeng Z, Chen M, Zhang S. A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn's Disease. Front Immunol 2021;12:646673. [PMID: 34367126 DOI: 10.3389/fimmu.2021.646673] [Reference Citation Analysis]